Oragenics

  • Revenue$87 KFY, 2021
  • Market Capitalization$38.4 M2022-07-26

OverviewSuggest Edit

Oragenics is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

TypePublic
Founded1996
HQTampa, FL, USMap
Websiteoragenics.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)7(+17%)
Revenue (FY, 2021)$87 K
Share Price (Jul 2022)$0.3(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Oragenics

Charles L. Pope

Charles L. Pope

Director
Michael Sullivan

Michael Sullivan

Chief Financial Officer and Interim Principal Executive Officer
Alan Dunton

Alan Dunton

Director
Robert Koski

Robert Koski

Director
Kim Murphy

Kim Murphy

Director
Show more

Oragenics Office Locations

Oragenics has an office in Tampa
Tampa, FL, US (HQ)
4902 Eisenhower Blvd N #125
Show all (1)

Oragenics Financials and Metrics

Oragenics Revenue

Oragenics's revenue was reported to be $86.99 k in FY, 2021
USD

Revenue (Q1, 2022)

15.1k

Net income (Q1, 2022)

(6.0m)

EBIT (Q1, 2022)

(6.1m)

Market capitalization (26-Jul-2022)

38.4m

Closing stock price (26-Jul-2022)

0.3

Cash (31-Mar-2022)

21.4m
Oragenics's current market capitalization is $38.4 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

1.4m1.3m1.0m939.9k1.2m87.0k

Revenue growth, %

(9%)25%(100%)

Cost of goods sold

713.6k878.5k343.4k369.6k481.7k

Gross profit

730.8k453.3k688.9k570.3k694.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

347.6k350.4k380.5k256.4k176.4k167.7k253.4k214.7k303.8k201.0k363.8k242.0k329.8k262.3k15.1k

Cost of goods sold

328.8k134.4k198.2k112.3k63.9k86.7k113.4k79.8k125.6k73.7k168.0k86.8k134.6k90.0k

Gross profit

18.8k215.9k182.3k144.1k112.5k81.0k140.0k134.9k178.1k127.3k195.8k155.3k195.2k172.3k

Gross profit Margin, %

5%62%48%56%64%48%55%63%59%63%54%64%59%66%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

171.7k9.9m16.3m10.4m5.1m4.1m6.2m20.2m18.3m17.6m27.3m

Accounts Receivable

92.6k69.8k64.4k15.6k21.1k24.1m7.0k

Prepaid Expenses

113.3k221.8k175.2k119.4k211.7k1.0m1.7m570.1k343.1k434.7k

Inventories

475.6k124.2k288.4k439.2k321.5k141.1k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

967.9k1.1m11.8m8.4m6.4m8.3m14.6m12.9m11.8m9.1m8.0m6.7m3.4m5.5m5.1m2.2m2.1m2.9m4.8m3.9m13.8m29.3m25.7m22.3m14.4m9.6m36.5m34.6m29.9m21.4m

Accounts Receivable

55.1k44.3k63.3k39.4k72.4k55.4k49.6k58.9k42.9k22.8k26.3k29.6k26.8k19.4k32.7k

Prepaid Expenses

168.3k123.9k152.3k236.4k210.5k302.4k227.0k154.4k144.6k221.6k133.8k90.4k173.3k192.9k111.8k171.9k106.3k517.7k769.6k722.6k1.3m1.7m1.7m355.4k555.5k328.7k295.5k222.8k86.9k586.5k277.5k

Inventories

500.6k465.5k363.0k353.8k279.9k117.3k303.0k223.3k265.9k239.0k263.9k377.0k364.1k299.3k241.5k
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(7.7m)(13.1m)(16.1m)(5.8m)(11.7m)(7.0m)(6.7m)(9.9m)(15.6m)(26.4m)(15.7m)

Depreciation and Amortization

79.5k75.2k76.5k27.7k71.2k75.0k65.8k30.1k62.6k51.7k41.2k

Inventories

(209.0k)351.4k(164.2k)(150.8k)117.7k

Accounts Payable

225.3k(57.5k)(234.5k)(199.7k)331.1k446.0k525.8k225.3k498.1k(603.7k)10.6k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(3.9m)(5.7m)(1.6m)(8.5m)(11.1m)(1.6m)(3.7m)(13.0m)(1.6m)(3.5m)(4.6m)(1.3m)(7.6m)(9.5m)(2.1m)(2.4m)(4.3m)(2.0m)(3.2m)(5.3m)(2.1m)(4.4m)(7.2m)(3.3m)(8.1m)(12.0m)(5.2m)(17.5m)(5.2m)(9.0m)(13.4m)(6.0m)

Depreciation and Amortization

40.1k60.1k19.6k37.2k55.8k21.0k42.1k64.0k6.5k13.3k20.1k13.9k32.5k52.5k18.3k36.5k55.4k18.0k35.7k53.3k7.7k11.0k18.4k12.9k26.2k44.3k13.1k26.0k12.7k25.2k34.8k8.5k

Inventories

(233.9k)(198.8k)112.6k121.8k195.6k6.9k61.2k140.9k22.5k49.4k24.5k62.2k75.1k139.9k80.0k

Accounts Payable

96.4k29.0k11.7k1.7k(104.6k)(75.3k)64.9k(280.4k)(102.6k)(206.7k)(305.6k)(200.9k)(161.5k)51.6k17.0k(137.5k)(44.8k)(174.6k)(216.1k)317.2k293.4k719.1k548.5k931.8k697.7k851.4k245.3k(484.2k)(364.3k)993.3k586.2k146.5k
show all
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Oragenics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Oragenics Online and Social Media Presence

Oragenics's Trends

Embed Graph

Oragenics News and Updates

August 21, 2020

Thinking about buying stock in Oragenics Inc, Fortress Biotech, Super League Gaming, CleanSpark Inc, or iBio Inc?

NEW YORK, Aug. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, FBIO, SLGG, CLSK, and IBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 22, 2020

Thinking about buying stock in Oragenics Inc, Waitr Holdings, PDS Biotechnology, Novan Inc, or Ocugen Inc?

NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, WTRH, PDSB, NOVN, and OCGN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
October 04, 2018

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oragenics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Oragenics, Inc. (NYSE American: OGEN). If you...
October 03, 2018

Thinking about buying stock in DavidsTea, India Globalization Capital, Oragenics Inc, Stitch Fix or vTv Therapeutics?

NEW YORK, Oct. 3, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DTEA, IGC, OGEN, SFIX, and VTVT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Oragenics Blogs

June 14, 2022

Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the Nationa…
April 18, 2022

Oragenics to Participate at the World Vaccine Congress Washington 2022

Company to showcase NT-CoV2-1, a patient-friendly Covid vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, today announced that Kimberly Murphy…
April 06, 2022

Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

Agreement extends current licensing and collaboration agreement to include rapid production of intranasal vaccine candidates against future variants TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has extended a licensing a…
March 25, 2022

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 24, 2022 with the Securities and Exchange Commission,…
March 22, 2022

Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

Data to establish the safety profile and human dose of vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and im…
March 10, 2022

Oragenics Engages KBI Biopharma to Support Development of Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

KBI to produce material for use in future expected Phase 2 clinical trial of Oragenics' intranasal vaccine candidate TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has entered into an agreement with KBI Biopharma, Inc. (“K…
Show more

 Oragenics Frequently Asked Questions

  • When was Oragenics founded?

    Oragenics was founded in 1996.

  • Who are Oragenics key executives?

    Oragenics's key executives are Charles L. Pope, Michael Sullivan and Alan Dunton.

  • How many employees does Oragenics have?

    Oragenics has 7 employees.

  • What is Oragenics revenue?

    Latest Oragenics annual revenue is $87 k.

  • What is Oragenics revenue per employee?

    Latest Oragenics revenue per employee is $12.4 k.

  • Who are Oragenics competitors?

    Competitors of Oragenics include Genprex, Izun Pharmaceuticals and Bionnovation.

  • Where is Oragenics headquarters?

    Oragenics headquarters is located at 4902 Eisenhower Blvd N #125, Tampa.

  • Where are Oragenics offices?

    Oragenics has an office in Tampa.

  • How many offices does Oragenics have?

    Oragenics has 1 office.